Delcath Systems
Delcath Systems
Delcath Systems (pronounced: Del-kath Systems) is a specialty pharmaceutical and medical device company focused on oncology. Its primary product is the Melphalan/HDS system, which is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Etymology
The name "Delcath" is a portmanteau of the founders' names, but the exact etymology is not publicly known.
History
Delcath Systems was founded in 1988 and is headquartered in New York City. The company's initial focus was on the development of new devices for the treatment of metastatic cancers. Over the years, Delcath Systems has expanded its product portfolio to include the Melphalan/HDS system.
Melphalan/HDS
The Melphalan/HDS (pronounced: Mel-fa-lan/HDS) system is a proprietary product of Delcath Systems. It is a percutaneous hepatic perfusion system that delivers high doses of melphalan hydrochloride directly to the liver. The system is designed to minimize systemic exposure to the chemotherapy drug, thereby reducing potential side effects.
Related Terms
- Oncology: The branch of medicine that deals with the prevention, diagnosis, and treatment of cancer.
- Metastasis: The spread of cancer cells from the place where they first formed to another part of the body.
- Chemotherapy: A type of cancer treatment that uses drugs to kill cancer cells.
- Melphalan: A chemotherapy drug used to treat multiple myeloma, a type of blood cancer.
- Hepatic perfusion: A procedure that sends chemotherapy directly to the liver.
External links
- Medical encyclopedia article on Delcath Systems
- Wikipedia's article - Delcath Systems
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski